

DOCUMENT MADE AVAILABLE UNDER THE PATENT COOPERATION TREATY (PCT)

International application number:	PCT/CA2015/050626
International filing date:	07 July 2015 (07.07.2015)
Document type:	Certified copy of priority document
Document details:	Country/Office: US
	Number: 62/091,943
	Filing date: 15 December 2014 (15.12.2014)
Date of receipt at the International Bureau:	13 August 2015 (13.08.2015)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a),(b) or (b-bis)

29 July 2015 (29.07.2015)

PA 7539081



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

July 10, 2015

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 62/091,943

FILING DATE: December 15, 2014

THE COUNTRY CODE AND NUMBER OF YOUR PRIORITY
APPLICATION, TO BE USED FOR FILING ABROAD UNDER THE PARIS
CONVENTION, IS US62/091,943

By Authority of the
Under Secretary of Commerce for Intellectual Property
and Director of the United States Patent and Trademark Office




T. WALLACE

Certifying Officer

Electronic Acknowledgement Receipt

EFS ID:	20964630
Application Number:	62091943
International Application Number:	
Confirmation Number:	7648
Title of Invention:	METHODS FOR THE TREATMENT OF HEPATITIS B AND HEPATITIS D INFECTIONS
First Named Inventor/Applicant Name:	Andrew Vaillant
Customer Number:	20988
Filer:	Demian Barbas
Filer Authorized By:	
Attorney Docket Number:	05016051-40USPR1
Receipt Date:	15-DEC-2014
Filing Date:	
Time Stamp:	16:29:08
Application Type:	Provisional

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$130
RAM confirmation Number	3531
Deposit Account	195113
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		Application.pdf	176519	yes	35
			f31d17be99e545b4ef5e1a848075f74b38c6e262		
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Specification		1	21	
	Claims		22	32	
	Abstract		33	33	
	Drawings-only black and white line drawings		34	35	
Warnings:					
Information:					
2	Sequence Listing (Text File)	SequenceListing.TXT	5624	no	0
Warnings:					
Information:					
3	Provisional Cover Sheet (SB16)	ProvisionalCoverSheet.PDF	1477384	no	3
			831dd60380ba70915eb5b61dcee807111c54abb2		
Warnings:					
Information:					
4	Fee Worksheet (SB06)	fee-info.pdf	29843	no	2
			8910bc4d4c329878c3f50ea889635e7beef1c019		
Warnings:					
Information:					
Total Files Size (in bytes):			1689370		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Doc Code: TR.PROV

Document Description: Provisional Cover Sheet (SB16)

PTO/SB/16 (11-08)

Approved for use through 05/31/2015. OMB 0651-0032

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Provisional Application for Patent Cover Sheet

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c)

Inventor(s)

Inventor 1

Remove

Given Name	Middle Name	Family Name	City	State	Country ;
Andrew		Vaillant	Roxboro	QC	CA

Inventor 2

Remove

Given Name	Middle Name	Family Name	City	State	Country ;
Michel		Bazinet	Montreal	QC	CA

All Inventors Must Be Listed – Additional Inventor Information blocks may be generated within this form by selecting the **Add** button.**Add**

Title of Invention	METHODS FOR THE TREATMENT OF HEPATITIS B AND HEPATITIS D INFECTIONS
---------------------------	---

Attorney Docket Number (if applicable)	05016051-40USPR1
--	------------------

Correspondence Address

Direct all correspondence to (select one):

☒ The address corresponding to Customer Number	☐ Firm or Individual Name
---	---

Customer Number	20988
-----------------	-------

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

- ☒ No.
- ☐ Yes, the invention was made by an agency of the United States Government. The U.S. Government agency name is:
- ☐ Yes, the invention was under a contract with an agency of the United States Government. The name of the U.S. Government agency and Government contract number are:

Doc Code: **TR.PROV**

Document Description: Provisional Cover Sheet (SB16)

PTO/SB/16 (11-08)

Approved for use through 05/31/2015. OMB 0851-0032

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Entity Status**Applicant asserts small entity status under 37 CFR 1.27 or applicant certifies micro entity status under 37 CFR 1.29**

- ☒ Applicant asserts small entity status under 37 CFR 1.27
- ☐ Applicant certifies micro entity status under 37 CFR 1.29. Applicant must attach form PTO/SB/15A or B or equivalent.
- ☐ No

Warning

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

Signature

Please see 37 CFR 1.4(d) for the form of the signature.

Signature	/Demian Barbas/			Date (YYYY-MM-DD)	2014-12-15
First Name	Demian	Last Name	Barbas	Registration Number (If appropriate)	65750

This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. This form can only be used when in conjunction with EFS-Web. If this form is mailed to the USPTO, it may cause delays in handling the provisional application.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

05016051-40USPR1

-1-

METHODS FOR THE TREATMENT OF HEPATITIS B AND HEPATITIS D INFECTIONS

TECHNICAL FIELD

[0001] The present description relates to methods of treating a subject with hepatitis B infection or hepatitis B/hepatitis D virus co-infection comprising administering a first pharmaceutically acceptable phosphorothioated nucleic acid polymer formulation and a second pharmaceutically acceptable nucleoside/nucleotide analog formulation that inhibits the hepatitis B polymerase.

BACKGROUND ART

[0002] The hepatitis B virus (HBV) afflicts 400 million individuals worldwide and causes an estimated 600,000 deaths each year from complications arising from HBV infection. While several antiviral treatments are approved for use, none of these is able to elicit a therapeutically effective immune response capable of providing durable control of infection except in a small fraction of patients undergoing treatment.

[0003] HBV infection results in the production of two different particles: 1) the infectious HBV virus itself (or Dane particle) which includes a viral capsid assembled from the HBV core antigen protein (HBcAg) and is covered by the hepatitis B surface antigen (HBsAg) and 2) subviral particles (or SVPs) which are high density lipoprotein-like particles comprised of lipids, cholesterol, cholesterol esters and the small and medium forms of the hepatitis B surface antigen (HBsAg) which are non-infectious. For each viral particle produced, 1,000-10,000 SVPs are released into the blood. As such SVPs (and the HBsAg protein they carry) represent the overwhelming majority of viral protein in the blood. HBV infected cells also secrete a soluble proteolytic product of the pre-core protein called the HBV e-antigen (HBeAg).

[0004] The hepatitis D virus (HDV) uses HBsAg to form its viral structure (Taylor, 2006, Virology, 344: 71-76) and as such, HDV infection can only occur in subjects with concomitant HBV infection. While the incidence of HDV co-infection in asymptomatic HBV carriers and chronic HBV-related liver disease is low in countries with a low incidence of HBV infection, it is a significant complication in HBV-infected subjects in countries with a high incidence of HBV infection and can increase the

05016051-40USPR1

-2-

rate of progression of liver disease to liver cirrhosis. The unmet medical need in HBV infection is even more pressing in HBV/HDV co-infected subjects; there is no specific approved agent that directly targets the HDV virus and patient response even to combination therapy with approved agents for HBV treatment is poorer than patients with HBV mono-infection (Wedemeyer et al., 2014, Oral abstract 4, 49th Annual Meeting of the European Association for the Study of the Liver, April 9-14, London, UK).

[0005] The current approved treatments for HBV include interferon- α or thymosin α 1-based immunotherapies and the suppression of viral production by inhibition of the HBV polymerase by nucleoside / nucleotide analogs. HBV polymerase inhibitors are effective in reducing the production of infectious virions but have little to no effect in reducing HBsAg or only very slowly reduce HBsAg with long term treatment in a limited number of patients (Fung et al., 2011, Am. J. Gastroenterol., 106: 1766-1773; Reijnders et al., 2011, J. Hepatol., 54: 449-454; Charuworn et al., 2014, Poster abstract 401, 48th Annual Meeting of the European Association for the Study of the Liver, April 24-28, Amsterdam, The Netherlands). The primary effect of HBV polymerase inhibitors is to block the transformation of pre-genomic viral mRNA into partially double stranded DNA, which is infectious. Interferon based immunotherapy can achieve a reduction of infectious virus and removal of HBsAg from the blood but only in a small percentage of treated subjects.

[0006] HBsAg in the blood can sequester anti-HBsAg antibodies and allow infectious viral particles to escape immune detection which is likely one of the reasons why HBV infection remains a chronic condition. In addition HBsAg, HBeAg and HBcAg all have immuno-inhibitory properties as discussed below and the persistence of these viral proteins in the blood of patients following the administration of any of the currently available treatments for HBV as described above likely has a significant impact in preventing patients from achieving immunological control of their HBV infection.

[0007] Although the three primary HBV proteins (HBsAg, HBeAg and HBcAg) all have immuno-inhibitory properties (see below), HBsAg comprises the overwhelming majority of HBV protein in the circulation of HBV infected subjects and is likely the primary mediator of inhibition of the host immune response to HBV infection. While

05016051-40USPR1

-3-

the removal of HBeAg, appearance of anti-HBe or reductions in serum viremia are not correlated with the development of sustained control of HBV infection off treatment, the removal of serum HBsAg from the blood (and appearance of free anti-HBsAg antibodies) in HBV infection is a well-recognized excellent prognostic indicator of antiviral response on treatment which will lead to control of HBV infection off treatment (although this only occurs in a small fraction of patients receiving immunotherapy or HBV polymerase inhibitors). Thus, while reduction of all three major HBV proteins (HBsAg, HBeAg and HBcAg) may result in the optimal removal of inhibitory effect, the removal of HBsAg is essential and its removal alone is likely sufficient to remove the bulk of the inhibition of immune function in subjects with HBV infection.

[0008] Another critical feature of chronic HBV infection is the establishment of a stable reservoir of HBV genetic information in the nucleus of infected cells called covalently closed circular DNA (cccDNA). cccDNA exists in multiple copies within the nucleus as an extrachromosomal episome which functions as the transcriptional template for the production of mRNA encoding all viral proteins and immature genomes (pre-genomic mRNA) for the production of new virions. After encapsidation in the cytoplasm, the immature pre-genomic mRNA is converted into a mature, partially double stranded DNA genome by the HBV polymerase (which is co-encapsidated with the pregenomic mRNA), thereby rendering the mature HBV genome competent to establish or replenish a cccDNA reservoir in naïve or previously infected cells. The end of the infectious process consists of the delivery of this partially double stranded genomic HBV template into the nucleus and its conversion to cccDNA.

[0009] cccDNA can be replenished in the nucleus of infected cells via nuclear import of HBV capsids containing mature HBV genomes which replenish the cccDNA copy number. This nuclear cccDNA replenishment is accomplished by two mechanisms: direct nuclear import of assembled capsids from the cytoplasm or re-infection of previously infected hepatocytes with subsequent shuttling of the internalized capsids into the nucleus (Rabe et al., 2003, Proc. Natl. Acad. Sci. USA, 100: 9849-9854). The transcriptional inhibition or elimination of this genomic HBV

05016051-40USPR1

-4-

reservoir in the nucleus is critical to the establishment of long term control of HBV infection following treatment.

[0010] Long term treatment with nucleoside / nucleotide HBV polymerase inhibitors can reduce cccDNA copy number within the nucleus, consistent with the ability of HBV polymerase inhibitors to block replenishment of cccDNA by nuclear import of capsids containing mature HBV genomes. However, while cccDNA copy number is reduced, it still remains transcriptionally active thus HBsAg levels remain largely unaffected (Werle-Lapostolle et al., 2004, Gastroenterol., 126: 1750-1758; Wong et al., 2013, Clin. Gastroenterol. Hepatol., 11: 1004-1010; Wong et al., 2014, Poster abstract 1074, 49th Annual Meeting of the European Association for the Study of the Liver, April 9-14, London, UK). cccDNA can be transcriptionally inactivated by immune-mediated processes (Belloni et al., 2012, J. Clin. Inv., 122: 529-537) but the ability of the immune response to provoke cytokine responses required for cccDNA inactivation is likely blocked by persistently circulating HBsAg as described in U.S. 2014/0065102 (which is incorporated herein by reference in its entirety) and is consistent with the ineffectiveness of immunotherapies in treating HBV infection.

[0011] As such, there exists a clear unmet medical need for a treatment regimen which can elicit a durable immunological control of HBV infection in a large proportion of patients receiving this treatment.

SUMMARY

[0012] In accordance with the present description there is now provided a method for the treatment of HBV infection or HBV/HDV co-infection in a subject requiring such treatment, the method comprising the administration of a first pharmaceutically acceptable agent which comprises at least one phosphorothioated nucleic acid polymer and a second pharmaceutically acceptable agent which comprises at least one nucleoside/nucleotide analog HBV polymerase inhibitor.

[0013] It is further provided the use of a first pharmaceutically acceptable agent which comprises at least one phosphorothioated nucleic acid polymer and a second pharmaceutically acceptable agent which comprises at least one nucleoside/nucleotide analog HBV polymerase inhibitor for treating HBV infection or HBV/HDV co-infection in a subject.

05016051-40USPR1

-5-

[0014] It is additionally provided the use of a first pharmaceutically acceptable agent which comprises at least one phosphorothioated nucleic acid polymer and a second pharmaceutically acceptable agent which comprises at least one nucleoside / nucleotide analog HBV polymerase inhibitor in the manufacture of a medicament for treating HBV infection or HBV/HDV co-infection in a subject.

[0015] It is also provided a composition comprising a first pharmaceutically acceptable agent which comprises at least one phosphorothioated nucleic acid polymer and a second pharmaceutically acceptable agent which comprises at least one nucleoside/nucleotide analog HBV polymerase inhibitor for treating HBV infection or HBV/HDV co-infection in a subject.

[0016] In another embodiment, the nucleic acid polymer comprises a phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence AC.

[0017] In another embodiment, nucleic acid polymer comprises a phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising the repeats of the sequence CA.

[0018] In another embodiment, the nucleic acid polymer comprises a phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising the repeats of the sequence TG.

[0019] In another embodiment, the nucleic acid polymer comprises a phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising the repeats of the sequence GT.

[0020] In another embodiment, the phosphorothioated nucleic acid polymer further comprises at least one 2' ribose modification.

[0021] In another embodiment, the phosphorothioated nucleic acid polymer further comprises all riboses having a 2' modification.

[0022] In another embodiment, the phosphorothioated nucleic acid polymer further comprises at least one 2' O methyl ribose modification.

05016051-40USPR1

-6-

[0023] In another embodiment, the phosphorothioated nucleic acid polymer further comprises all riboses having the 2' O methyl modification.

[0024] In another embodiment, the phosphorothioated nucleic acid polymer further comprises at least one 5'methylcytosine.

[0025] In another embodiment, the phosphorothioated nucleic acid polymer further comprises all cytosines present as 5'methylcytosine.

[0026] In another embodiment, the phosphorothioated nucleic acid polymer further comprises at least one 2' ribose modification and at least one 5' methylcytosine.

[0027] In another embodiment, the phosphorothioated nucleic acid polymer further comprises all riboses having the 2' O methyl modification and all cytosines present as 5'methylcytosine.

[0028] In another embodiment, the nucleic acid polymer is selected from the group consisting of SEQ ID NOs: 1-20.

[0029] In another embodiment, the nucleic acid polymer is prepared as an oligonucleotide chelate complex comprising an oligonucleotide selected from the group consisting of SEQ ID NOs: 1-20.

[0030] In another embodiment, the nucleic acid polymer is an oligonucleotide consisting of SEQ ID NO: 2.

[0031] In another embodiment, the nucleic acid polymer is prepared as an oligonucleotide chelate complex comprising SEQ ID NO: 2.

[0032] In another embodiment, the nucleic acid polymer is an oligonucleotide consisting of SEQ ID NO: 10.

[0033] In another embodiment, the nucleic acid polymer is prepared as an oligonucleotide chelate complex comprising SEQ ID NO: 10.

[0034] In another embodiment, nucleic acid polymer is an oligonucleotide consisting of SEQ ID NO: 13.

05016051-40USPR1

-7-

[0035] In another embodiment, the nucleic acid polymer is prepared as an oligonucleotide chelate complex comprising SEQ ID NO: 13.

[0036] In a further embodiment, the first and second pharmaceutically acceptable agents are formulated within the same pharmaceutical composition.

[0037] In a further embodiment, the first and second agents are formulated within separate pharmaceutical compositions.

[0038] In a further embodiment, the first and second agents are formulated for a simultaneous administration.

[0039] In a further embodiment, first and second agents are formulated for an administration by a different route.

[0040] In a further embodiment, the first and second agents are formulated for an administration using one or more of the following: oral ingestion, aerosol inhalation, subcutaneous injection, intravenous injection and intravenous infusion.

[0041] In a further embodiment, the nucleic acid polymer is at least one of:

SEQ ID NO: 2;

SEQ ID NO: 10;

SEQ ID NO: 13;

SEQ ID NOs: 1, 3-9, 11, 12 and 14-20;

a phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence AC;

a phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence CA;

a phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence TG and

a phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence GT.

[0042] In a further embodiment, the following nucleic acid polymers can be further formulated as an oligonucleotide chelate complex:

05016051-40USPR1

-8-

SEQ ID NO: 2;

SEQ ID NO: 10;

SEQ ID NO 13;

SEQ ID NOs: 1, 3-9, 11, 12 and 14-20;

a phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence AC;

a phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence CA;

a phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence TG; and

a phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence GT.

[0043] In another embodiment, the nucleoside/nucleotide analog HBV polymerase inhibitor comprises one or more of the following:

lamivudine;

adefovir dipivoxil;

entecavir;

telbivudine;

tenofovir disoproxil fumarate;

entricitabine;

clevudine;

besifovir;

tenofovir alafenamide fumarate;

AGX-1009;

elvucitabine;

lagociclovir valactate;

pradefovir mesylate;

valtorcitabine; and

any nucleoside / nucleotide analog which inhibits the HBV polymerase.

05016051-40USPR1

-9-

BRIEF DESCRIPTION OF THE DRAWINGS

[0044] Fig. 1 illustrates the synergistic effect of combination therapy with the NAP REP 2055 (SEQ ID NO: 2) and entecavir (ETV) on the reduction of serum levels of HBsAg.

[0045] Fig. 2A illustrates the antiviral activity of NAPs administered to infected Pekin ducks with DHBV measured by monitoring serum DHBsAg by ELISA.

[0046] Fig. 2B illustrates the antiviral activity of NAPs administered to infected Pekin ducks with DHBV assessed by monitoring liver DHBV DNA by quantitative PCR.

DETAILED DESCRIPTION

[0047] It is provided herein a combination therapy against HBV infection which consists of administering a first pharmaceutically acceptable agent capable of removing HBsAg from the blood and a second pharmaceutically acceptable agent which inhibits the HBV polymerase. Such a combination treatment allows recovery of host immune function (by removal of serum HBsAg) which in turn leads to the immune-mediated transcriptional inactivation of cccDNA and or reduction of cccDNA copy number in infected hepatocytes while simultaneously blocking replenishment of cccDNA via nuclear import of capsids containing mature HBV genomes (by inhibiting the HBV polymerase). The combined synergistic effects of these two agents accelerates the elimination of cccDNA from infected cells, thus shortening the time of therapy required to obtain sustained suppression of infection off treatment. Importantly, these effects can be achieved in the absence of immunotherapy. This combination treatment will be effective in HBV monoinfection and HBV/HDV co-infection.

[0048] HBsAg plays a key role in HBV infection and HBV/HDV co-infection. Aside from its role as an essential structural component for virion formation, HBsAg is also released in large amounts into the blood of infected subjects in the form of subviral particles (SVPs), which lack the viral capsid and genome and which appear to function primarily to deliver HBsAg into the blood. SVPs are secreted from infected cells in 1,000-10,000 fold excess over virus secretion which allows SVPs to

05016051-40USPR1

-10-

effectively sequester HBsAg antibodies (anti-HBs) so that HBV or HDV virus in the blood can escape recognition by adaptive immunity. Several studies have also suggested that HBsAg may also function to directly block activation of adaptive and innate immune responses to HBV infection (Cheng et al., 2005, *Journal of hepatology*, 43:4 65-471; Op den Brouw et al., 2009, *Immunology*, 126: 280-289; Vanlandschoot et al., 2002, *The Journal of general virology*, 83: 1281-1289; Wu et al., 2009, *Hepatology*, 49: 1132-1140; Xu et al., 2009, *Molecular immunology*, 46: 2640-2646). The presence of this functionality in human HBV infection and its impact on the activity of immunotherapeutic agents and the additional applicability of these antiviral effects in HBV/HDV co-infection has been previously described in US 2014/0065102 A1, which is incorporated herein by reference in its entirety. Although HBeAg and HBcAg have also been shown to have immuno-inhibitory properties (Kanda et al., 2012, *J. Inf. Dis.*, 206: 415-420; Lang et al., 2011, *J. Hepatol.*, 55: 762-769; Gruffaz et al., 2013, *J. Hepatol.*, 58 (supp1), p s155, Abstract 378), these are likely of minimal impact given the very small proportion of HBeAg and HBcAg in relation to HBsAg in the blood.

[0049] DHBV-infected ducks are an accepted model of HBV infection and have been used in the evaluation of several HBV antiviral agents currently used to treat human patients (Schultz et al., 2004, *Adv Virus Res*, 63:1-70; Foster et al., 2005, *J Virol*, 79:5819-5832; Nicoll et al., 1998, *Antimicrob Agents Chemother.*, 42:3130-3135). Nucleic acid polymers (NAPs) that are phosphorothioated have been shown to have antiviral activity in DHBV infected ducks and clearance of serum duck HBsAg (DHBsAg) by the NAP REP 2055 (SEQ ID NO:2) led to the subsequent transcriptional inactivation of cccDNA and reduction in cccDNA copy number in DHBV infected duck hepatocytes in vivo (Noordeen et al., 2009, Abstract 88 HEPDART meeting Dec 6 – 9, HI, USA). This inactivation and elimination of cccDNA is caused by removal of DHBsAg-mediated repression of the host immune function, which can then inactivate and clear cccDNA from infected cells by recognized, immune-mediated mechanisms (Levrero et al., 2009, *J. Hepatol.*, 51: 581-592; Belloni et al., 2012, *J. Clin. Inv.*, 122: 529-537).

[0050] The only agents proven to effectively remove HBsAg from the blood of human patients are phosphorothioated NAPs as described in US 2014/0065102 and

05016051-40USPR1

-11-

in an accepted preclinical model of HBV infection (duck HBV infected Pekin ducks), the restored immune function in the absence of serum duck HBsAg was able to both transcriptionally inactivate and eliminate cccDNA from infected hepatocytes (Noordeen et al., 2009, Abstract 88, HEPDART meeting Dec 6-10, HI, USA). Thus, removal of HBsAg from the serum of HBV infected patients is expected to have the same effect on cccDNA inactivation in infected human hepatocytes in situ.

[0051] Therefore, it is described herein an effective means for establishing durable control of cccDNA activity and or its elimination from HBV infected hepatocytes which consists of a novel combined approach whereby HBsAg is reduced or eliminated from the blood by the use of a pharmaceutically acceptable phosphorothioated NAP formulation and replenishment of cccDNA is blocked by a second pharmaceutically acceptable nucleotide/nucleoside analog formulation inhibiting the HBV polymerase. This combined approach has the following novel and important benefits:

- 1) it combines the ability of an improved host immune function (caused by removal of serum HBsAg) to transcriptionally inactivate and or reduce cccDNA copy number within the cell with the blockade of cccDNA replenishment (by preventing capsids containing mature genomes from entering the nucleus (by inhibition of HBV polymerase activity);
- 2) it has a synergistic effect on reducing the duration of treatment required to remove, eliminate or establish transcriptional suppression of cccDNA from infected hepatocytes in the liver because of the overlapping effects of said two pharmaceutically acceptable agents; and
- 3) it does not require the use of an immunotherapy (as taught to be specifically required in U.S. 2014/0065102) to achieve sustained control of HBV infection after treatment which would be an important therapeutic improvement, given the poor tolerability of immunotherapy in many patients.

[0052] The transcriptional inactivation and or removal of cccDNA from infected hepatocytes by the methods described above has the same therapeutic benefit in patients with HBV mono-infection and HBV/HDV co-infection as HDV infection cannot exist in the absence of HBV infection as described above.

05016051-40USPR1

-12-

[0053] Therefore, in the absence of any current treatment regimen which can either eliminate or establish durable control of cccDNA activity without the use of immunotherapy in a large proportion of patients, it is provided herein for the first time an effective combination treatment against HBV infection and HBV/HDV co-infection which simultaneously reduces or clears HBsAg from the blood and which blocks cccDNA replenishment in the nucleus of HBV infected cells. These effects can be achieved by the use of a pharmaceutically acceptable phosphorothioated NAP formulation used in combination with a pharmaceutically acceptable nucleoside / nucleotide analog HBV polymerase inhibitor.

[0054] This novel combination approach is effective in the absence of immunotherapy, which has the important advantages of improving the tolerability of treatment and reducing the incidence of hematological and other side effects known to occur with immunotherapy.

[0055] The term oligonucleotide (ON) refers to an oligomer or polymer of ribonucleic acid (RNA) and/or deoxyribonucleic acid (DNA). This term includes ONs composed of modified nucleobases (including 5'methylcytosine and 4'thiouracil), sugars and covalent internucleoside (backbone) linkages as well as ONs having non-naturally-occurring portions which function similarly. Such modified or substituted ONs may be preferable over native forms because of desirable properties such as, for example, reduced immunoreactivity, enhanced cellular uptake, enhanced affinity for the nucleic acid target (in the context of antisense ONs, siRNAs and shRNAs) and / or increased stability to nuclease-mediated degradation. ONs can also be double stranded. ONs also include single stranded molecules such as antisense oligonucleotides, Speigelmers and aptamers and miRNAs, as well as double stranded molecules such as small interfering RNAs (siRNAs) or small hairpin RNAs (shRNAs).

[0056] ONs can include various modifications, e.g., stabilizing modifications, and thus can include at least one modification in the phosphodiester linkage and/or on the sugar, and/or on the base. For example, the ON can include, without restriction, one or more modifications, or be fully modified so as to contain all linkages or sugars or bases with the recited modifications. Modified linkages can include phosphorothioate linkages and phosphorodithioate linkages. While modified linkages

05016051-40USPR1

-13-

are useful, the ONs can include phosphodiester linkages. Additional useful modifications include, without restriction, modifications at the 2'-position of the sugar including 2'-O-alkyl modifications such as 2'-O-methyl modifications, 2' O-methoxyethyl (2' MOE), 2'-amino modifications, 2'-halo modifications such as 2'-fluoro; acyclic nucleotide analogs. Other 2' modifications are also known in the art and can be used such as locked nucleic acids. In particular, the ON has modified linkages throughout or has every linkage modified, e.g., phosphorothioate; has a 3'-and/or 5'-cap; includes a terminal 3'-5' linkage; the ON is or includes a concatemer consisting of two or more ON sequences joined by a linker(s). Base modifications can include 5'methylation of the cytosine base (5' methylcytosine or in the context of a nucleotide, 5' methylcytidine) and/or 4'thioation of the uracil base (4'thiouracil or in the context of a nucleotide, 4'thiouridine). Different chemically compatible modified linkages can be combined where the synthesis conditions are chemically compatible such as having an oligonucleotide with phosphorothioate linkages, a 2' ribose modification (such as 2'O-methylation) and a modified base (such as 5'methylcytosine). The ON can further be completely modified with all of these different modifications (e.g. each linkage phosphorothioated, each ribose 2' modified and each base being modified).

[0057] As encompassed herein, the term "nucleic acid polymer" or NAP is any single stranded ON which contains no sequence specific functionality, either to hybridize with a nucleic acid target or adopt a sequence specific secondary structure which results in binding to a specific protein. The biochemical activity of NAPs are not dependent on Toll-like receptor recognition of ONs, hybridization with a target nucleic acid or aptameric interaction requiring a specific secondary/tertiary ON structure derived from a specific order of nucleotides present. NAPs can include base and or linkage and or sugar modifications as described above. NAPs require phosphorothioation to have antiviral activity. Exemplary antiviral NAP compounds are listed in table 1.

05016051-40USPR1

-14-

Table 1

Examples of antiviral NAPs which can be useful in the current disclosure.

Nucleic acid type	Sequence (5' – 3')	Modifications
DNA	(dAdC) ₂₀ (SEQ ID NO: 2)	All linkages PS
DNA	(dCdA) ₂₀ (SEQ ID NO: 1)	All linkages PS
DNA	(dA-5'MeC) ₂₀ (SEQ ID NO: 3)	All linkages PS
DNA	(5'MeC-dA) ₂₀ (SEQ ID NO: 4)	All linkages PS
RNA	(AC) ₂₀ (SEQ ID NO: 5)	All linkages PS All riboses with 2'OMe modification
RNA	(CA) ₂₀ (SEQ ID NO: 6)	All linkages PS All riboses with 2'OMe modification
DNA	(dTdG) ₂₀ (SEQ ID NO: 7)	All linkages PS
DNA	(dGdT) ₂₀ (SEQ ID NO: 8)	All linkages PS
RNA	(5'MeC-A) ₂₀ (SEQ ID NO: 9)	All linkages PS All riboses with 2'OMe modification
RNA	(A-5'MeC) ₂₀ (SEQ ID NO: 10)	All linkages PS All riboses with 2'OMe modification
RNA / DNA	(A-5'MeC) ₂₀ (SEQ ID NO: 11)	All linkages PS All riboses on riboadenosine are 2'OMe modified
RNA	(A-5'MeC) ₂₀ (SEQ ID NO: 12)	All linkages PS All riboses with 2'OMe modification except riboadenosines at positions 13 and 27
RNA-	(A-5'MeC) ₂₀ (SEQ ID NO: 13)	All linkages PS All riboses with 2'OMe modification except riboadenosines at positions 11, 21 and 31
RNA	(A-5'MeC) ₂₀ (SEQ ID NO: 14)	All linkages PS All 5'MeC riboses are 2'OMe modified
RNA / DNA	(dA-5'MeC) ₂₀ (SEQ ID NO: 15)	All linkages PS All 5'MeC riboses are 2'OMe modified
RNA / DNA	(5'MeC-A) ₂₀ (SEQ ID NO: 16)	All linkages PS All A riboses are 2'OMe modified
RNA	(5'MeC-A) ₂₀ (SEQ ID NO: 17)	All linkages PS All riboses with 2'OMe modification except riboadenosines at positions 14 and 28
RNA	(5'MeC-A) ₂₀ (SEQ ID NO: 18)	All linkages PS All riboses with 2'OMe modification except riboadenosines at positions 10, 20 and 30
RNA	(5'MeC-A) ₂₀ (SEQ ID NO: 19)	All linkages PS All 5'MeC riboses are 2'OMe modified
RNA / DNA	(5'MeC-dA) ₂₀ (SEQ ID NO: 20)	All linkages PS All 5'MeC riboses are 2'OMe modified

dA = deoxyadenosine, A = adenosine, dC = deoxycytidine, C = cytidine, dT = deoxythymidine, dG = deoxyguanosine, PS = phosphorothioate, 2'OMe = 2' O methyl, 5'MeC = 5'methylcytosine-modified cytidine, 5'MeC = 5'methylcytosine-modified deoxycytidine

[0058] In the present disclosure, the term "ON chelate complex" refers to two or more ONs linked intermolecularly by a divalent or multivalent metal cation and can

05016051-40USPR1

-15-

occur with single or double stranded ONs. ON chelate complexes neutralize the inherent chelation properties of ONs which can contribute to administration-related side effects with these compounds. The administration of ON chelate complexes is a method of administering an ON to a subject where administration-related side effects associated with un-chelated ONs (which are ONs administered as sodium salts as is commonly used in the art) are mitigated as described in U.S. 8,513,211 and 8,716,259, which are incorporated herein by reference in their entirety. These side effects may include shivering, fever and chills with intravenous infusion or induration, inflammation and pain at the injection site with subcutaneous administration. The administration of ON chelate complexes does not interfere with the biochemical activity of ONs when used normally as sodium salts. Thus any NAP described herein can be optionally prepared as an ON chelate complex without affecting its biochemical activity.

[0059] ON chelate complexes may contain diverse multivalent metal cations including calcium, magnesium, cobalt, iron, manganese, barium, nickel, copper, zinc, cadmium, mercury and lead. It is further demonstrated that chelation of these multivalent metal cations results in the formation of ON chelate complexes comprised of two or more ONs linked via metal cations and occur with ONs greater than 6 nucleotides in length, and in the presence of ONs with either phosphodiester or phosphorothioate linkages. ONs can optionally have each linkage phosphorothioated. Chelation also occurs with ONs containing 2' modifications (such as 2' O methyl) at the ribose or containing modified bases such as 5'methylcytosine or 4-thiouracil. These 2' modifications can be present on one or more or all riboses and modified bases can be present on one or more bases or be universally present on each base (i.e. all cytosines are present as 5'methylcytosine). Additionally, the ON chelate complexes can comprise ONs which contain multiple modifications such as each linkage phosphorothioated, each ribose 2' modified and each base modified. ON modifications compatible with ON chelate complex formation are further defined above. Moreover, the chelation of the metal cations is not dependent on the sequence of nucleotides present but instead relies on the physiochemical features common to all ONs.

05016051-40USPR1

-16-

[0060] While the formation of ON chelate complexes can be achieved with any divalent metal cation, ON chelate complexes intended for use as medications should preferably contain only calcium and or magnesium but could also contain iron, manganese, copper or zinc in trace amounts and should not include cobalt, barium, nickel, cadmium, mercury, lead or any other divalent metal not listed herein.

[0061] As described in U.S. 2014/0065192, the removal of HBsAg from the blood of infected patients by phosphorothioated NAPs results in a partial restoration of the immune response which in turn removes HBV e-antigen (HBeAg) from the blood and results in substantial reduction of levels of virus in the blood during treatment but these antiviral effects are not maintained in most patients after treatment is stopped. While this partial restoration of the immune response (in the absence of HBsAg and other viral antigens) can lead to the establishment of durable immunological control of HBV infection after treatment is stopped in a small proportion of patients, it is not sufficient to achieve this control off treatment in the majority of patients treated. Thus the approach of simply removing HBsAg from the blood by using any pharmaceutically acceptable agent with this effect will provide only the same moderate level of immunological recovery that will result in the establishment of durable control off treatment in a limited proportion of patients.

[0062] The term "removal of HBsAg from the blood" as used herein means any statistically significant reduction of the concentration HBsAg in the blood relative to pre-treatment HBsAg blood concentrations as measured by the Abbott Architect™ quantitative HBsAg assay or other clinically accepted quantitative measure of serum HBsAg.

[0063] Exemplary effective dosing regimens for phosphorothioated NAPs follow those typically used for other phosphorothioated ONs (such as antisense oligonucleotides) as described in U.S. 2014/0065102; the routine use of weekly parenteral administration of 100-500 mg of compound is well established in the art to result in the achievement of therapeutically active levels of these compounds in the liver as described for the NAPs in example I below and for a phosphorothioated antisense ON causing the degradation of a liver specific mRNA (for apolipoprotein B100) as described in Akdim et al. (2010, Journal of the American College of Cardiology, 55: 1611-1618).

05016051-40USPR1

-17-

[0064] Therefore, according to the disclosures presented herein, it is useful to treat a subject with HBV infection or HBV/HDV co-infection with a pharmaceutically acceptable phosphorothioated NAP formulation combined with a pharmaceutically acceptable nucleoside/nucleotide HBV polymerase inhibitor.

[0065] It is also useful to administer both pharmaceutically acceptable agents in the same pharmaceutical composition or to administer both pharmaceutically acceptable agents in separate pharmaceutical compositions at the same time or at different times.

[0066] It is useful to administer the pharmaceutically acceptable agents by the same or different routes of administration.

[0067] In order to provide the best possible antiviral response in a subject, it may be necessary to use more than one HBV polymerase inhibitor to maximally block the HBV polymerase and thus have maximal greater effect on blocking the replenishment of cccDNA. Thus one or more HBV polymerase inhibitors can be selected from the following nucleoside analogs:

- lamivudine;
- adefovir dipivoxil;
- entecavir;
- telbivudine;
- tenofovir disoproxil fumarate;
- entricitabine;
- clevudine;
- besifovir;
- tenofovir alafenamide fumarate;
- AGX-1009;
- elvucitabine;
- lagociclovir valactate;
- pradefovir mesylate;
- valtorcitabine; and
- any nucleoside / nucleotide analog which inhibits the HBV polymerase.

05016051-40USPR1

-18-

[0068] The compositions described herein may be administered by any suitable means, for example, orally, such as in the form of tablets, capsules, granules or powders; sublingually; buccally; parenterally, such as by subcutaneous, intravenous, injection or infusion techniques (e.g., as sterile injectable aqueous or non-aqueous solutions or suspensions); by inhalation; topically, such as in the form of a cream or ointment; or rectally such as in the form of suppositories or enema; in dosage unit formulations containing non-toxic, pharmaceutically acceptable vehicles or diluents. The present compositions may, for example, be administered in a form suitable for immediate release or extended release. Immediate release or extended release may be achieved by the use of suitable pharmaceutical compositions, or, particularly in the case of extended release, by the use of devices such as subcutaneous implants or osmotic pumps. Thus, the above compositions may be adapted for administration by any one of the following routes: oral ingestion, inhalation, subcutaneous injection, , intravenous injection or infusion, or topically.

[0069] The present disclosure will be more readily understood by referring to the following example.

EXAMPLE I

Effect of combination NAP / ETV therapy on serum HBsAg

[0070] A pharmaceutically acceptable formulation of the NAP REP 2055 (SEQ ID NO: 2) was administered to a patient with chronic HBV infection by once weekly IV infusion of 400mg. The serum HBsAg response in this patient was monitored real-time each week using a qualified, on-site qualitative ELISA. This ELISA method is very sensitive to low levels of HBsAg but cannot accurately quantify any significant HBsAg concentration in the blood. Although no detectable reduction in serum HBsAg was observed using this HBsAg assay during REP 2055 monotherapy (fig. 1, squares), this patient experienced a very mild (~ 1 log) drop in serum viremia (serum HBV DNA), indicating that some sort of antiviral response had occurred. Therefore, after 29 weeks of REP 2055 monotherapy, this patient received HBV polymerase inhibition therapy in addition to the existing REP 2055 therapy which consisted of 0.5mg of entecavir taken orally every day.

05016051-40USPR1

-19-

[0071] Immediate reductions in serum HBsAg were detected by the qualitative assay within two weeks of starting combination REP 2055/ETV therapy and serum HBsAg became undetectable in the qualitative ELISA within 4 weeks after starting combination treatment (Fig. 1, squares). This synergistic control of serum HBsAg with combined REP 2055 / ETV treatment was maintained over many weeks of treatment.

[0072] To confirm the synergistic activity of combination REP 2055 / ETV therapy on suppression of HBsAg, serum samples from this patient were re-analyzed using the IMPACT platform to accurately quantitate serum HBsAg levels as described in de Neit et al. (2014, Antiviral Ther., 19: 259-267). This quantitative analysis revealed an initial ~ 2 log reduction of serum HBsAg occurred with REP 2055 monotherapy (Fig. 1 circles), which was not detectable by the qualitative ELISA and which was likely the cause of the observed ~ 1 log drop in viremia on REP 2055 monotherapy described above. Importantly, serum HBsAg reduction in this patient reached a plateau where significant serum HBsAg was stably present starting from 10 weeks of REP 2055 treatment until the start of combination REP 2055/ETV therapy at 29 weeks of treatment. With the onset of combination REP 2055/ETV treatment, the quantitative analysis of serum HBsAg demonstrated an almost identical and rapid reduction in serum HBsAg as observed with the onsite qualitative test, with these additional reductions exceeding 1.5 logs which were also accomplished within 4 weeks after the start of combination REP 2055/ETV treatment.

[0073] The persistence of low levels of serum HBsAg in the presence of REP 2055 monotherapy is an indication that cccDNA was still present in the liver of this patient which was transcriptionally active. The very rapid additional clearance of serum HBsAg with the addition of ETV to existing REP 2055 therapy is an indication that a synergistic effect on cccDNA transcriptional control and or elimination had occurred. Importantly, the development of this additional control of cccDNA occurred much more rapidly than observed with HBV polymerase inhibitors used in monotherapy, requiring only 4 weeks to achieve. Therefore, these observations are a demonstration of the novel, synergistic antiviral effect of serum HBsAg reduction (in this case achieved using the NAP REP 2055) when combined with an HBV polymerase inhibitor (in this case entecavir).

05016051-40USPR1

-20-

EXAMPLE II**Antiviral effects of various NAPs in DHBV infected Pekin Ducks**

[0074] Various NAPs comprising different nucleic acid modifications were tested in DHBV infected Pekin ducks to establish their antiviral activity. These NAPs are REP 2055 (SEQ ID NO: 2), REP 2139 (SEQ ID NO: 10), REP 2163 (SEQ ID NO: 11) and REP 2165 (SEQ ID NO: 13). Table 2 provides a chemical description of these NAPs.

Table 2
Description of NAPs used in Example II

NAP	Sequence	Oligonucleotide modifications present
REP 2055 (SEQ ID NO: 2)	(dAdC) ₂₀	Each linkage is phosphorothioated
REP 2139 (SEQ ID NO: 10)	(A, 5'MeC) ₂₀	Each linkage is phosphorothioated Every ribose is 2'O methylated
REP 2163 (SEQ ID NO: 11)	(A, 5'MedC) ₂₀	Each linkage is phosphorothioated Only the riboses in adenosine are 2'O methylated
REP 2165 (SEQ ID NO: 13)	(A, 5'MeC) ₂₀	Each linkage is phosphorothioated Every ribose is 2'O methylated except adenosines at positions 11, 21 and 31 where riboses are 2'OH.

dA = deoxyriboadenosine

dC = deoxyribocytidine

A = riboadenosine

5'MeC = ribo-5' methylcytidine

5'MedC = deoxyribo-5' methylcytidine

[0075] Three-day-old Pekin ducklings were infected with 2×10^{11} viral genome equivalents (VGE)/ml of DHBV. NAP treatment was started 11 days later after infection had become established. NAPs were administered via intraperitoneal injection with 10mg/kg of NAPs (formulated as calcium chelate complexes) 3 times/week for three weeks followed by analysis of antiviral effect at the end of treatment. A control group was treated with normal saline via the same route of administration and with the same dosing regimen. Antiviral activity was assessed by monitoring serum DHBsAg by ELISA (Fig. 2A) and liver DHBV DNA by quantitative PCR (Fig. 2B).

[0076] All NAPs gave comparable reductions in serum DHBsAg and liver DHBV DNA, demonstrating that different NAPs containing diverse oligonucleotide modifications will have comparable antiviral effect. This in turn indicates that the

05016051-40USPR1

-21-

synergistic antiviral activity observed with the use of a specific NAP and one or more nucleoside analog based HBV polymerase inhibitors (as observed with REP 2055 and entecavir in Example I above) will occur with any other phosphorothioated NAP and also with said NAP formulated as a chelate complex (as described in U.S. 8,513,211 and 8,716,259).

[0077] These observations teach that any pharmaceutically acceptable phosphorothioated NAP formulation which reduces or removes HBsAg from the blood (as described in U.S. 2014/0065102 and U.S. 8,008,269, 8,008,270 and 8,067,385) could be combined with any nucleoside/nucleotide HBV polymerase inhibitor as listed above and be expected to achieve a similarly synergistic effect on the transcriptional inactivation and or elimination of HBV cccDNA. The synergistic effects observed also teach that lower doses of said pharmaceutically acceptable agents could be combined and still achieve a synergistic activity with a useful antiviral effect.

[0078] Given the synergistic antiviral effects observed above with one phosphorothioated NAP used in combination with one nucleoside/nucleotide HBV polymerase inhibitor, a superior synergistic effect could also be achieved with one or more phosphorothioated NAPs used in combination with one or more nucleoside/nucleotide HBV polymerase inhibitors as described above.

[0079] The above description is meant to be exemplary only, and one skilled in the art will recognize that changes may be made to the embodiments described without departing from the scope of the invention as defined by the appended claims. Still other modifications which fall within the scope of the present invention, as defined in the appended claims, will be apparent to those skilled in the art, in light of a review of this disclosure.

05016051-40USPR1

-22-

WHAT IS CLAIMED IS:

1. A method for treating hepatitis B infection or hepatitis B / hepatitis D co-infection in a subject comprising administering a first pharmaceutically acceptable agent which comprises at least one phosphorothioated nucleic acid polymer and a second pharmaceutically acceptable agent which comprises at least one nucleoside / nucleotide analog HBV polymerase inhibitor.
2. A method of treating hepatitis B infection or hepatitis B / hepatitis D co-infection in a subject comprising administering a first pharmaceutically acceptable agent which comprises one or more nucleic acid polymers selected from the following:

SEQ ID NO: 2;

SEQ ID NO: 10;

SEQ ID NO 13;

SEQ ID NOs: 1, 3-9, 11, 12 and 14-20;

a phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence AC;

a phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence CA;

a phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence TG and

a phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence GT;

and a second pharmaceutically acceptable agent which comprises one or more of the following:

lamivudine;

adefovir dipivoxil;

entecavir;

telbivudine;

tenofovir disoproxil fumarate;

emtricitabine;

clevudine;

05016051-40USPR1

-23-

besifovir;
tenofovir alafenamide fumarate;
AGX-1009;
elvucitabine;
lagociclovir valactate;
pradefovir mesylate;
valtorcitabine; and
any nucleoside / nucleotide analog which inhibits the HBV polymerase.

3. The method of claim 1 or 2, wherein the nucleic acid polymer further comprises at least one 2' ribose modification.
4. The method of any one of claims 1-3, wherein the nucleic acid polymer further comprises all riboses having a 2' modification.
5. The method of any one of claims 1-4, wherein the nucleic acid polymer further comprises at least one 2' O methyl ribose modification.
6. The method of any one of claims 1-5, wherein the nucleic acid polymer further comprises all riboses having the 2' O methyl modification.
7. The method of any one of claims 1-6, wherein the nucleic acid polymer further comprises at least one 5'methylcytosine.
8. The method of any one of claims 1-7, wherein the nucleic acid polymer further comprises all cytosines present as 5'methylcytosine.
9. The method of any one of claims 1-8, wherein the nucleic acid polymer further comprises at least one 2' O methyl ribose modification and at least one 5' methylcytosine.

05016051-40USPR1

-24-

10. The method of any one of claims 1-9, wherein the nucleic acid polymer further comprises all riboses having the 2' O methyl modification and all cytosines present as 5'methylcytosine.

11. The method of any one of claims 2-10, wherein the following nucleic acid polymers are further formulated as an oligonucleotide chelate complex:

SEQ ID NO: 2;

SEQ ID NO: 10;

SEQ ID NO 13;

SEQ ID NOs: 1, 3-9, 11, 12 and 14-20;

the phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence AC;

the phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence CA;

the phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence TG and

the phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence GT.

12. The method of any one of claims 1-11, wherein said first and second pharmaceutically acceptable agents are formulated within the same pharmaceutical composition.

13. The method of any one of claims 1-11, where said first and second agents are formulated within separate pharmaceutical compositions.

14. The method of any one of claims 1-13, wherein said first and second agents are administered simultaneously.

15. The method of any one of claims 1-11 and 13, wherein said first and second agents are administered by a different route.

05016051-40USPR1

-25-

16. The method of any one of claims 1-15, wherein said first and second agents are administered using one or more of the following: oral ingestion, aerosol inhalation, subcutaneous injection, intravenous injection and intravenous infusion.

17. Use of a first pharmaceutically acceptable agent which comprises at least one phosphorothioated nucleic acid polymer and a second pharmaceutically acceptable agent which comprises at least one nucleoside / nucleotide analog hepatitis B polymerase inhibitor for treating HBV infection or hepatitis B / hepatitis D co-infection in a subject.

18. Use of a first pharmaceutically acceptable agent which comprises at least one phosphorothioated nucleic acid polymer and a second pharmaceutically acceptable agent which comprises at least one nucleoside / nucleotide analog hepatitis B polymerase inhibitor in the manufacture of a medicament for treating hepatitis B infection or hepatitis B / hepatitis D co-infection in a subject.

19. Use of a first pharmaceutically acceptable agent which comprises one or more nucleic acid polymers selected from the following:

SEQ ID NO: 2;

SEQ ID NO: 10;

SEQ ID NO 13;

SEQ ID NOs: 1, 3-9, 11, 12 and 14-20;

a phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence AC;

a phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence CA;

a phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence TG and

a phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence GT;

and a second pharmaceutically acceptable agent which comprises one or more of the following:

05016051-40USPR1

-26-

lamivudine;
adefovir dipivoxil;
entecavir;
telbivudine;
tenofovir disoproxil fumarate;
entricitabine;
clevudine;
besifovir;
tenofovir alafenamide fumarate;
AGX-1009;
elvucitabine;
lagociclovir valactate;
pradefovir mesylate;
valtorcitabine; and
any nucleoside / nucleotide analog which inhibits the HBV polymerase

for the treatment of hepatitis B infection or hepatitis B / hepatitis D co-infection.

20. Use of a first pharmaceutically acceptable agent which comprises one or more nucleic acid polymers selected from the following:

SEQ ID NO: 2;
SEQ ID NO: 10;
SEQ ID NO 13;
SEQ ID NOs: 1, 3-9, 11, 12 and 14-20;
a phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence AC;
a phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence CA;
a phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence TG and
a phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence GT;

05016051-40USPR1

-27-

and a second pharmaceutically acceptable agent which comprises one or more of the following:

- lamivudine;
- adefovir dipivoxil;
- entecavir;
- telbivudine;
- tenofovir disoproxil fumarate;
- entricitabine;
- clevudine;
- besifovir;
- tenofovir alafenamide fumarate;
- AGX-1009;
- elvucitabine;
- lagociclovir valactate;
- pradefovir mesylate;
- valtorcitabine; and
- any nucleoside / nucleotide analog which inhibits the HBV polymerase

in the manufacture of a medicament for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection.

21. The use of any one of claims 17-20, wherein the nucleic acid polymer further comprises at least one 2' ribose modification.

22. The use of any one of claims 17-21, wherein the nucleic acid polymer further comprises all riboses having a 2' modification.

23. The use of any one of claims 17-22, wherein the nucleic acid polymer further comprises at least one 2' O methyl ribose modification.

24. The use of any one of claims 17-23, wherein the nucleic acid polymer further comprises all riboses having a 2' O methyl modification.

05016051-40USPR1

-28-

25. The use of any one of claims 17-24, wherein the nucleic acid polymer further comprises at least one 5'methylcytosine.

26. The use of any one of claims 17-25, wherein the nucleic acid polymer further comprises all cytosines present as 5'methylcytosine.

27. The use of any one of claims 17-26, wherein the nucleic acid polymer further comprises at least one 2' O methyl ribose modification and at least one 5' methylcytosine.

28. The use of any one of claims 17-27, wherein the nucleic acid polymer further comprises all riboses having the 2' O methyl modification and all cytosines present as 5'methylcytosine.

29. The use of any one of claims 19-28, wherein the following nucleic acid polymers are further formulated as an oligonucleotide chelate complex:

SEQ ID NO: 2;

SEQ ID NO: 10;

SEQ ID NO 13;

SEQ ID NOs: 1, 3-9, 11, 12 and 14-20;

the phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence AC;

the phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence CA;

the phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence TG; and

the phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence GT.

30. The use of any one of claims 17-29, wherein said first and second pharmaceutically acceptable agents are formulated within the same pharmaceutical composition.

05016051-40USPR1

-29-

31. The use of any one of claims 17-29, wherein said first and second agents are formulated within separate pharmaceutical compositions.

32. The use of any one of claims 17-31, wherein said first and second agents are formulated for a simultaneous administration.

33. The use of any one of claims 17-29 and 31, wherein said first and second agents are formulated for an administration by a different route.

34. The use of any one of claims 17-33, wherein said first and second agents are formulated for an administration using one or more of the following: oral ingestion, aerosol inhalation, subcutaneous injection, intravenous injection and intravenous infusion.

35. A composition comprising a first pharmaceutically acceptable agent which comprises at least one phosphorothioated nucleic acid polymer and a second pharmaceutically acceptable agent which comprises at least one nucleoside / nucleotide analog hepatitis B polymerase inhibitor for treating hepatitis B infection or hepatitis B / hepatitis D co-infection in a subject.

36. A composition comprising a first pharmaceutically acceptable agent which comprises one or more nucleic acid polymers selected from the following:

SEQ ID NO: 2;

SEQ ID NO: 10;

SEQ ID NO 13;

SEQ ID NOs: 1, 3-9, 11, 12 and 14-20;

a phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence AC;

a phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence CA;

a phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence TG and

05016051-40USPR1

-30-

a phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence GT;

and a second pharmaceutically acceptable agent which comprises one or more of the following:

- lamivudine;
- adefovir dipivoxil;
- entecavir;
- telbivudine;
- tenofovir disoproxil fumarate;
- entricitabine;
- clevudine;
- besifovir;
- tenofovir alafenamide fumarate;
- AGX-1009;
- elvucitabine;
- lagociclovir valactate;
- pradefovir mesylate;
- valtorcitabine; and
- any nucleoside / nucleotide analog which inhibits the HBV polymerase

for the treatment of hepatitis B infection or hepatitis B / hepatitis D co-infection.

37. The composition of claim 35 or 36, wherein the nucleic acid polymer further comprises at least one 2' ribose modification.

38. The composition of any one of claims 35-37, wherein the nucleic acid polymer further comprises all riboses having a 2' modification.

39. The composition of any one of claims 35-38, wherein the nucleic acid polymer further comprises at least one 2' O methyl ribose modification.

40. The composition of any one of claims 35-39, wherein the nucleic acid polymer further comprises all riboses having a 2' O methyl modification.

05016051-40USPR1

-31-

41. The composition of any one of claims 35-40, wherein the nucleic acid polymer further comprises at least one 5'methylcytosine.

42. The composition of any one of claims 35-41, wherein the nucleic acid polymer further comprises all cytosines present as 5'methylcytosine.

43. The composition of any one of claims 35-42, wherein the nucleic acid polymer further comprises at least one 2' ribose modification and at least one 5' methylcytosine.

44. The composition of any one of claims 35-43, wherein the nucleic acid polymer further comprises all riboses having the 2' O methyl modification and all cytosines present as 5'methylcytosine.

45. The composition of any one of claims 35-44, wherein the following nucleic acid polymers are further formulated as an oligonucleotide chelate complex:

SEQ ID NO: 2;

SEQ ID NO: 10;

SEQ ID NO 13;

SEQ ID NOs: 1, 3-9, 11, 12 and 14-20;

the phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence AC;

the phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence CA;

the phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence TG; and

the phosphorothioated oligonucleotide from 20-120 nucleotides in length comprising repeats of the sequence GT.

46. The composition of any one of claims 35-45, wherein said composition is formulated for an administration using one or more of the following: oral ingestion,

05016051-40USPR1

-32-

aerosol inhalation, subcutaneous injection, intravenous injection and intravenous infusion.

05016051-40USPR1

-33-


ABSTRACT OF THE DISCLOSURE

It is disclosed a method for treating hepatitis B infection or hepatitis B / hepatitis D co-infection, the method comprising administering to a subject in need of such treatment a first pharmaceutically acceptable agent that comprises at least one phosphorothioated nucleic acid polymer and a second pharmaceutically acceptable agent that comprises at least one nucleoside / nucleotide analog HBV polymerase inhibitor.

05016051-40USPR1

-34-

Fig. 1



* below cut-off for serum HBsAg detection in local ELISA (HBsAg negative)

05016051-40USPR1

-35-

Fig. 2A




Fig. 2B

